The new generation weight-loss drug developed by the U.S. biotechnology company Metsera, Inc. (MTSR) demonstrated excellent ...

The drugs are part of a new generation of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

The Trump administration on Thursday rolled out a much-anticipated deal with drugmakers Eli Lilly and Novo Nordisk that aims ...

Novo Nordisk and Eli Lilly said they've agreed to sell their blockbuster drugs Wegovy and Zepbound at a discount.

Novo Nordisk A/S has again increased its offer for Metsera Inc. as its takeover battle with Pfizer Inc. for the obesity ...

Presented by the Coalition to Strengthen America’s Healthcare — State Medicaid programs that choose to participate in the model will be able to purchase drugs included in the pilot at prices ...

CMS introduced the GENEROUS Model to reduce Medicaid drug costs, enhance access, and improve health outcomes for ...

President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to reduce prices for their obesity ...

Amylin is a peptide co-secreted with insulin in response to food intake. It controls gastric emptying, inhibits glucagon secretion, and promotes satiety. Several amylin receptor agonists are in ...

On this week’s episode of "The Readout LOUD," melodrama at the top of the FDA and the latest on the Pfizer-Novo Nordisk ...

US President Donald Trump announced deals Thursday with pharmaceutical giants Eli Lilly and Novo Nordisk to lower the prices ...

Trump announced new deals with Eli Lilly and Novo Nordisk to lower GLP-1 costs for Medicare, Medicaid, and cash-paying patients.